AZN
AstraZeneca PLC (AZN) is a key player in the global pharmaceutical industry, with a substantial market capitalization of $226.208 billion. The stock's Price-to-Earnings (P/E) ratio of 35.35 suggests that investors have high expectations for the company's earnings potential, possibly driven by its robust portfolio of innovative medicines and therapies.
The Return on Equity (ROE) of 16.74% indicates that AstraZeneca is efficiently generating profits from shareholders' equity. However, it's important to note that while the company's ROE is healthy, it is not extremely high, suggesting room for growth in leveraging equity more effectively. The debt-to-equity ratio of 84.97 highlights that the company utilizes a moderate level of debt in its capital structure, which could be a strategic approach to finance its operations and growth initiatives.
AstraZeneca's current ratio of 0.889 indicates that the company may face challenges in covering short-term liabilities, suggesting a need for careful management of its current assets and liabilities. On the positive side, the operating margin of 22.42% and an EBITDA margin of 34.55% reflect strong operational efficiency and profitability in its core business activities.
The company's free cash flow of approximately $9.82 billion is a significant indicator of its financial health, enabling AstraZeneca to reinvest in business growth, including Research and Development (R&D) for new treatments. However, investors should be aware of the trailing PEG ratio of 0.84, suggesting that the stock might be undervalued relative to its earnings growth prospects, presenting a potential investment opportunity.
AstraZeneca's earnings growth is modest at 6%, while its revenue growth at 13.3% is considerably stronger, indicating a positive trend in the company's ability to expand its market reach and attract new customers. With institutions holding 17.11% of shares, there is visible institutional confidence in AstraZeneca's long-term strategy and market potential.
This overview provides a comprehensive analysis of AstraZeneca's financial standing, highlighting both strengths and areas requiring attention, crucial for investors assessing the pharmaceutical giant's potential for sustainable growth and robust returns.
Last Updated: January 14, 2025
| Metric | Value |
|---|---|
| Market Cap | 203.68 B |
| P/E Ratio | 31.58 |
| ROE | 16.66 % |
| Debt to Equity | 77.473 |
| Operating Margin | 20.40 % |
| Free Cash Flow | 9.51 B |
| Institutional Holdings | 16.77 % |
| Revenue Growth | 18.00 % |
Delve into AstraZeneca's Competitive Landscape and Market Dynamics
- Oncology: In the oncology space, AstraZeneca battles giants like Roche and Bristol-Myers Squibb. While innovation is rife, competition is fierce, compelling AstraZeneca to continuously evolve its portfolio.
- Cardiovascular and Metabolic Diseases: In the realm of cardiovascular and metabolic treatments, AstraZeneca vies with stalwarts like Novartis and Merck. These rivals, with robust legacies in the pharmaceutical industry, exemplify both the opportunities and challenges AstraZeneca faces.
- Respiratory: AstraZeneca's respiratory treatments contend with the likes of GSK and Pfizer. The quest for effective respiratory solutions underscores a vibrant but challenging competitive landscape.
- Biologics and Rare Diseases: AstraZeneca's foray into biologics and rare diseases brings it into competition with biotech innovators like Amgen and Biogen. This segment showcases the promise of cutting-edge science amid vigorous competition.
- Vaccines: In the fast-paced domain of vaccines, AstraZeneca competes with powerful entities like Pfizer and Moderna. The landscape here is driven by innovation and rapid response, requiring agility from all players.
AstraZeneca weaves a compelling narrative of ambition and challenge in the pharmaceutical sector. Its journey is marked by innovation and resilience against robust competition. For investors, tracking AstraZeneca’s strategic maneuvers and adaptability in facing current and emerging rivals will provide important insights into its future trajectory and potential for long-term growth.
Disclaimer: The information provided here is for educational and informational purposes only. While we strive to ensure the accuracy and reliability of the data, we do not make any guarantees regarding its completeness or accuracy. The analysis and metrics provided should not be considered as investment advice, and any actions taken based on this information are at your own risk. We do not assume responsibility for any financial losses or other damages incurred from the use of this data. Please consult with a qualified financial advisor before making any investment decisions.